Drug Trial Radar · NCT05905614
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Nov 3, 2020
Primary completion
Oct 26, 2023
Study completion Oct 26, 2023
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
SPH4336 TabletsDrug
Open-label SPH4336 Tablets :Administered by oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose(MTD)Time frame: Up to 28 days
- Dose-limiting toxicity (DLT)Time frame: Up to 28 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, China
Chongqing University Cancer Hospital
Chongqing, China
Jinan Central Hospital
Jinan, Shandong, China
West China Hospital,Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.